Obstructive Sleep Apnea (OSA): How to Prep for Your First Visit

What OSA Is and Why the Diagnosis Matters

OSA is a condition in which the upper airway collapses repeatedly during sleep, causing oxygen desaturation, sleep fragmentation, and systemic stress. The American Academy of Sleep Medicine (AASM) defines OSA as an AHI of 5 or more events per hour in the presence of symptoms, or an AHI of 15 or more events per hour regardless of symptoms. [1]

The AHI Scale

Severity is stratified as mild (AHI 5 to 14), moderate (AHI 15 to 29), and severe (AHI ≥30). Each tier carries different cardiovascular and metabolic risk. A 2020 analysis in the Journal of Clinical Sleep Medicine found that severe OSA (AHI ≥30) was independently associated with a 2.1-fold increased risk of incident hypertension over 12 years. [2]

Why Early Diagnosis Changes Outcomes

Untreated OSA raises the risk of motor vehicle accidents, type 2 diabetes, atrial fibrillation, and all-cause mortality. The Sleep Heart Health Study (N=6,441) found that men in the highest AHI quartile had a 42% higher all-cause mortality rate compared with those in the lowest quartile over a median follow-up of 8.2 years. [3] Identifying the condition early gives you and your clinician the full range of treatment options before those risks compound.

The STOP-BANG Questionnaire: Your Pre-Visit Homework

The STOP-BANG score is an eight-item screening tool validated for predicting moderate-to-severe OSA. A score of 3 or more identifies high-risk patients with a sensitivity of 93% for moderate-to-severe OSA. [4] Complete it before your appointment so your clinician can triage your urgency quickly.

The Eight STOP-BANG Items

The questions cover: Snoring loudly enough to be heard through closed doors, Tiredness or sleepiness during the day, Observed apneas, a history of high blood Pressure, Body mass index above 35, Age over 50, Neck circumference above 40 cm, and male Gender. One point per "yes." Bring your total to the visit.

Epworth Sleepiness Scale

The Epworth Sleepiness Scale (ESS) quantifies daytime sleepiness across eight common scenarios, each scored 0 to 3. A total above 10 suggests excessive daytime sleepiness and strengthens the case for prompt sleep testing. [5] The official ESS is freely available and takes under three minutes to complete.

What to Track in the Two Weeks Before Your Appointment

Your clinician needs objective data, not just a general sense that you "sleep badly." Specific numbers accelerate diagnosis.

A Sleep Diary

Record your estimated bedtime, approximate time to fall asleep, number of times you wake, final wake time, and a 1-to-10 subjective quality rating for each of the 14 nights before your visit. A structured sleep diary format endorsed by the AASM is available through the National Sleep Foundation. This two-week window captures weekday and weekend patterns, which often diverge.

Wearable or Consumer Device Data

Devices such as the Apple Watch, Fitbit, and Oura Ring can provide estimated sleep-stage data and blood oxygen trends. These are not diagnostic tools, but clinicians may find the longitudinal SpO2 graphs useful as supporting context. Export 14 days of data as a PDF or screenshot before your visit.

Medication and Supplement List

Several drug classes worsen OSA or affect polysomnography interpretation. Opioids, benzodiazepines, and muscle relaxants all suppress upper-airway tone. [6] Bring a full list, including doses and timing, so your clinician can assess pharmacological contributors.

Medical and Family History to Bring

Cardiovascular and Metabolic Conditions

Hypertension, atrial fibrillation, type 2 diabetes, and heart failure are all independently associated with OSA and may influence treatment urgency. [7] Have your most recent blood pressure readings available. If you have a home blood pressure cuff, record morning readings for one week before your appointment.

Anatomical Factors

Retrognathia (recessed jaw), enlarged tonsils, a Mallampati score of III or IV, and nasal septum deviation all predict difficult airway and higher OSA severity. Your clinician will assess these during the physical exam, but knowing your own ENT history saves time. Prior tonsillectomy, nasal surgery, or jaw procedures are all worth mentioning.

Family History

OSA has a heritable component. A 2015 twin study estimated the heritability of AHI at approximately 40%, attributed to shared craniofacial anatomy and obesity risk. [8] A first-degree relative with diagnosed OSA or a history of loud snoring raises your pre-test probability and may lower the threshold for ordering a sleep study.

Understanding the Two Diagnostic Tests

Home Sleep Apnea Test (HSAT)

An HSAT records airflow, respiratory effort, and pulse oximetry outside a lab setting. The AASM recommends HSAT as an acceptable alternative to PSG for adults with a high pre-test probability of moderate-to-severe OSA and no significant comorbidities such as heart failure or neuromuscular disease. [1] Results are typically available within a few days. The device is mailed to you, worn for one or two nights, and returned.

One important limitation: HSATs record total recording time rather than total sleep time, which means they systematically underestimate AHI. A clinician may order a confirmatory PSG if the HSAT result is negative but clinical suspicion remains high.

In-Lab Polysomnography (PSG)

PSG remains the gold-standard test. It captures EEG, EOG, EMG, airflow, respiratory effort, oximetry, and leg movements simultaneously. A 2017 Cochrane review found no statistically significant difference in CPAP adherence or daytime sleepiness outcomes between patients diagnosed by HSAT versus PSG, suggesting that for uncomplicated presentations, HSAT is a reasonable starting point. [9]

Treatment Options Your Clinician Will Discuss

CPAP Therapy

CPAP delivers pressurized air through a mask to splint the airway open during sleep. It is the first-line treatment for moderate-to-severe OSA across AASM, American Thoracic Society, and European Respiratory Society guidelines. [1] The APPLES trial (N=1,105) found that CPAP produced a statistically significant improvement in the Epworth Sleepiness Scale score (mean reduction 2.4 points, P<0.001) compared with sham CPAP at six months. [10]

CPAP adherence, defined as four or more hours of use on at least 70% of nights, averages around 50% in real-world studies. Mask fit is the single most modifiable determinant of adherence. Your clinician can refer you to a respiratory therapist for a mask-fitting session before or shortly after your diagnosis.

Mandibular Advancement Devices (MADs)

MADs are custom-fitted oral appliances that protrude the mandible to increase retroglossal airway space. They are most effective for mild-to-moderate OSA. A meta-analysis of 14 randomized controlled trials found MADs reduced AHI by a mean of 13.9 events per hour compared with baseline, versus 27.5 events per hour for CPAP. [11] Patients with CPAP intolerance are often good MAD candidates.

Positional Therapy

Roughly 56% of OSA patients have positional OSA, defined as an AHI at least twice as high in the supine position as in the lateral position. [12] For this subgroup, a positional therapy device (a wearable that vibrates to prompt position change) can reduce AHI substantially without a CPAP mask. Ask your clinician whether your HSAT or PSG data stratifies AHI by position.

Surgical Options

Upper airway surgery is reserved for patients who have failed CPAP and MADs, or who have specific anatomical obstruction (for example, enlarged tonsils, retrognathia). Hypoglossal nerve stimulation (Inspire therapy) was FDA-approved in 2014 and is indicated for moderate-to-severe OSA (AHI 15 to 65) in adults who cannot tolerate CPAP. [13] The STAR trial (N=126) found a 68% reduction in median AHI at 12 months post-implant. [13]

Tirzepatide (Zepbound) for OSA in Obesity

The FDA approved tirzepatide (Zepbound) in January 2024 specifically for moderate-to-severe OSA in adults with obesity (BMI ≥30). This is the first drug approval for OSA itself, not just for weight management as a secondary benefit. [14]

The approval was based on the SURMOUNT-OSA program, two Phase 3 randomized controlled trials. In SURMOUNT-OSA Trial 1 (participants not using CPAP, N=234), tirzepatide 10 or 15 mg weekly reduced AHI by a mean of 27.4 events per hour from baseline versus 4.8 events per hour with placebo at 52 weeks. In SURMOUNT-OSA Trial 2 (participants using CPAP, N=235), tirzepatide reduced AHI by 30.4 events per hour versus 6.0 with placebo. [15] The higher dose achieved the 62.8% relative AHI reduction cited in early analyses.

The SURMOUNT-OSA data also showed that 42.5% of tirzepatide-treated non-CPAP users achieved OSA remission (AHI <5) at 52 weeks versus 15.7% with placebo. [15] This means tirzepatide is not simply a CPAP adjunct for patients with obesity. For eligible patients, it may replace CPAP entirely.

The AACE 2024 obesity management guidelines now include GLP-1/GIP receptor agonists as first-tier pharmacotherapy for obesity-related comorbidities, which covers OSA in patients with BMI ≥30. [16]

Weight Loss and OSA: What the Evidence Shows

Body weight is the single most modifiable OSA risk factor. Fat deposition around the pharynx and tongue narrows the airway; fat in the thorax reduces functional residual capacity, further compromising respiratory mechanics during sleep.

The 10% Rule

A landmark longitudinal analysis from the Wisconsin Sleep Cohort Study found that a 10% weight reduction was associated with a 26% decrease in AHI, while a 10% weight gain was associated with a 32% increase in AHI. [17] These dose-response relationships are why structured weight management is now integrated into OSA treatment pathways, not just offered as an afterthought.

Lifestyle Intervention Alone

The Sleep AHEAD trial, a sub-study of the Look AHEAD trial (N=264 adults with type 2 diabetes and OSA), found that intensive lifestyle intervention producing a mean 10.8 kg weight loss reduced AHI by 9.7 events per hour versus 3.7 events per hour in the control arm at one year (P<0.001). [18] Patients who lost the most weight had the greatest OSA improvement, but very few achieved AHI remission through lifestyle alone.

When Pharmacotherapy Is Appropriate

Tirzepatide's approval specifically for OSA changes the decision tree. Patients with moderate-to-severe OSA and BMI ≥30 should now have a direct conversation with their clinician about whether tirzepatide is appropriate, either alongside CPAP or as primary therapy. The drug is administered as a once-weekly subcutaneous injection; doses are titrated from 2.5 mg weekly up to a target of 10 or 15 mg weekly over 20 weeks.

Questions to Ask at Your First Visit

Bring this printed list. Getting clear answers to each one sets realistic expectations and prevents confusion once test results arrive.

1. Based on my STOP-BANG score and symptoms, do you think I have mild, moderate, or severe OSA?
2. Will you order an HSAT or PSG, and why?
3. If my HSAT is negative, will we do a PSG anyway?
4. Do I need to stop any of my current medications before the sleep study?
5. Is my BMI a candidate for tirzepatide as an OSA treatment?
6. If I start CPAP, how will we measure whether it is working?
7. At what AHI or symptom threshold would you consider me in remission?
8. What is the realistic timeline from today to a confirmed diagnosis and treatment start?

Red Flags That Warrant Urgent Evaluation

Most OSA diagnoses are not emergencies, but some presentations do require faster action. Call your clinician or go to urgent care if you experience oxygen desaturation events (home pulse oximeter readings consistently below 88% during sleep), witnessed apneas lasting more than 20 seconds, new-onset nocturnal cardiac arrhythmias, or morning blood pressure spikes above 180/110 mmHg that resolve later in the day. [7]

Severe OSA in the context of right heart failure (cor pulmonale) or morbid obesity hypoventilation syndrome requires in-lab PSG and likely bilevel positive airway pressure (BiPAP) rather than standard CPAP. [1]

The Day-of-Visit Checklist

Arrive with these items ready:

• Completed STOP-BANG questionnaire (numerical score)
• Completed Epworth Sleepiness Scale (total out of 24)
• 14-night sleep diary
• Wearable SpO2 export, if available
• Full medication and supplement list with doses
• Insurance card and any prior sleep study results
• List of eight questions above, printed

The American Academy of Sleep Medicine notes that structured pre-visit preparation reduces the time from first appointment to treatment initiation by an estimated one to two weeks, because the clinician can order the sleep test at the same visit rather than scheduling a follow-up to gather missing information. [1]